Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   1 
  1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
Protocol Title: Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After 9 
Roux -en-Y Gastric By[CONTACT_42594]  10 
 11 
 12 
 13 
INVESTIGATOR -INITIATED STUDY PROTOCOL  14 
 15 
Universal Trial Number: U1111 -1178 -7319  16 
 17 
Regulatory Sponsor:  Holly Lofton, M.D.  
Director, Medical Weight Management Program  
Assistant Professor, Department of Surgery  
Assistant Professor, Department of Medicine  
NYU School of Medicine  
[ADDRESS_856638], S uite 10S  
[LOCATION_001], NY  [ZIP_CODE] -6497  
Tel: [PHONE_13299]  
Fax: [PHONE_13300]  
 
Funding:  Novo Nordisk  
Study Product:  Liraglutide  (rDNA origin) injection, Saxenda®  
Protocol Number:  NYULWMP -01, 16-[ZIP_CODE]  
Study ID: [REMOVED]  
 18 
 19 
 20 
Initial Version:  11/10 /2016  21 
Version 2: 06/01/2017  22 
Version 3:  10/25/2017  23 
Version 4:  12/11/2017  24 
Version 5:  04/12/2018  25 
Version 6:  02/13 /2019  26 
Version 7:  10/11/2019  27 
28 Clinical Research Protocol  

Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   2 
  29 
Table of Contents  30 
 31 
STUDY SUMMARY  ................................ ................................ ................................ ................................ ....... 6 32 
1 INTRODUCTION ................................ ................................ ................................ ................................ .. 7 33 
1.1 BACKGROUND AND SIGNIFICANCE  ................................ ................................ ................................ .........  7 34 
1.2 INVESTIGATIONAL AGENT ................................ ................................ ................................ .....................  7 35 
1.2.1  Name: [CONTACT_167818]®  (liraglutide (rDNA  origin)) or matching placebo  ................................ ................  7 36 
1.2.3  Indications  ................................ ................................ ................................ ................................ . 8 37 
1.2.4  Adult dosage  ................................ ................................ ................................ ..............................  8 38 
1.2.5  Administration  ................................ ................................ ................................ ............................  8 39 
1.2.6  Pharmacokinetics  ................................ ................................ ................................ .......................  8 40 
1.2.7  Mechanism of Action  ................................ ................................ ................................ ...................  9 41 
1.2.8  Contraindications  ................................ ................................ ................................ .......................  9 42 
1.2.9  Limitations of Use  ................................ ................................ ................................ .......................  9 43 
1.2.10  Precautions  ................................ ................................ ................................ ............................  9 44 
1.2.11  Storage & Stability  ................................ ................................ ................................ ...............  11 45 
1.3 PRECLINICAL DATA ................................ ................................ ................................ ............................  12 46 
1.4 CLINICAL DATA TO DATE ................................ ................................ ................................ ...................  12 47 
1.5 DOSE RATIONALE  ................................ ................................ ................................ ..............................  12 48 
1.6 RESEARCH RISKS & BENEFITS  ................................ ................................ ................................ .............  [ADDRESS_856639] SELECTION AND WITHDRAWAL ................................ ................................ ..................  16 64 
4.1 NUMBER OF THE SUBJECTS : [ADDRESS_856640] COMPLIANCE MONITORING  ................................ ................................ ................................ ... 20 78 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   3 
 5.4 CONCOMITANT THERAPY  ................................ ................................ ................................ ....................  20 79 
5.5 RECEIVING , STORAGE , DISPENSING AND RETURN  ................................ ................................ ..................  20 80 
5.5.1  Receipt of Drug Supplies  ................................ ................................ ................................ ...........  20 81 
5.5.2  Storage  ................................ ................................ ................................ ................................ .... 20 82 
5.6 METHOD FOR ASSIGNING SUBJECTS TO TREATMENT GROUPS AND DISPENSING OF STUDY DRUG ...............  20 83 
5.6.1  Randomization Process  ................................ ................................ ................................ .............  20 84 
5.6.2  Dispensing of Study Drug  ................................ ................................ ................................ ..........  21 85 
5.6.3  Return or Destruction of Study Drug  ................................ ................................ ..........................  21 86 
6 STUDY PROCEDURES  ................................ ................................ ................................ ......................  21 87 
1. FASTING IS REQUIRED  ................................ ................................ ................................ .........................  22 88 
6.1 VISIT 1 (BASELINE /PRE-TREATMENT ) ................................ ................................ ................................ .. 22 89 
6.1.1  Screening and Enrollment  ................................ ................................ ................................ .........  22 90 
6.1.2  Medical History  ................................ ................................ ................................ ........................  22 91 
6.1.3  Demographics  ................................ ................................ ................................ ..........................  22 92 
6.1.4  Physical Examination / Clinical Assessment ................................ ................................ ................  22 93 
6.1.5  Diet and Physical Activity Counseling  ................................ ................................ ........................  23 94 
6.1.6  Comorbidities Assessment  ................................ ................................ ................................ .........  23 95 
6.1.7  Blood work (total 25 ml blood collection)  ................................ ................................ ...................  23 96 
6.1.8  Questionnaires  ................................ ................................ ................................ .........................  24 97 
6.2 VISIT 2, 3, 4 (POST-TREATMENT ) ................................ ................................ ................................ .........  24 98 
6.2.1  Physical Examination / Clinical Assessment ................................ ................................ ................  [ADDRESS_856641] POPULATION (S) FOR ANALYSIS  ................................ ................................ ..............................  26 109 
7.4 INTERIM ANALYSIS  ................................ ................................ ................................ ............................  26 110 
8 SAFETY AND ADVERSE EVENTS  ................................ ................................ ................................ .... 26 111 
8.1 DEFINITIONS  ................................ ................................ ................................ ................................ ...... 26 112 
8.1.1  Unanticipated Problems Involving Risk to Subjects or Others  ................................ ......................  26 113 
8.1.2  Adverse Event  ................................ ................................ ................................ ...........................  26 114 
8.1.3  Serious Adverse Event  ................................ ................................ ................................ ...............  27 115 
8.1.4  Serious Adverse Drug Reaction (SADR)  ................................ ................................ .....................  [ADDRESS_856642] KEEPI[INVESTIGATOR_1645]  ................................ ................................ ..................  35 129 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856643] STIPENDS OR PAYMENTS  ................................ ................................ ................................ ... 38 143 
13 PUBLICATION PLAN  ................................ ................................ ................................ ........................  38 144 
14 REFERENCES  ................................ ................................ ................................ ................................ .... 39 145 
15 ATTACHMENTS  ................................ ................................ ................................ ................................  40 146 
147 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856644] of Abbreviations /Formula  148 
Term/Abbreviation  Definition  
ADR  Adverse Drug Reaction  
AE Adverse E vent 
 BMI  Body Mass I ndex  
BMP  Basic Metabolic Panel  
BMR  Basal Metabolic Rate  
 BP Blood pressure  
CPAP  Continuous Positive Airway P ressure  
CRF  Case Report F orm 
GCP  Good  Clinical Practice  
GI  Gastrointestinal  
GLP-[ADDRESS_856645]  Serious Adverse Drug Reaction  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SC Subcutaneous  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
TBWL  Total body weight loss  
UAE  Unexpected Adverse Event  
WL Weight loss (Baseline weight – Follow -up visit weight)  
 149 
150 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   6 
 Study Summary  151 
Title  Clinical Efficacy and Safety of Using  3.0mg Liraglutide to Treat Weight 
Regain After -Roux -en-Y Gastric By[CONTACT_640195] -01 
Phase  Phase 4 
Methodology  Randomized, double -blind, placebo controlled study  
Study Duration  Mar. 201 7 to Dec. 2020 
Study Center(s)  Single -center  
Objectives  The primary objective of this study is to assess the utility of  3.0mg liraglutide 
to reverse weight regain  versus placebo in patients at least [ADDRESS_856646] regained  of  ≥10%  of 
maximum TBWL (total body weight loss) after surgery . 
Number of Subjects  132 
Diagnosis and Main 
Inclusion Criteria  • ≥18 years who are deemed medically stable  
• ≥[ADDRESS_856647] RYGB  
• BMI 27 kg/m2 or greater in the presence of at least one weight -related 
comorbid condition  
• BMI 30 kg/m2 or greater   
• Regain  of  ≥10% of maximum TBWL post -RYGB   
• Ability to provide informed consent before any trial -related activities  
• Express willingness to follow protocol requirements  
Study Product, Dose, 
Route, Regimen  • Saxenda ® (Liraglutide (rDNA origin) ) injection, pre -dose pen  
• Solution for subcutaneous injection, pre -filled, multi -dose pen that 
delivers dose of 0.6mg,1.2mg, 1.8 mg, 2.4mg or 3 .0mg (6mg/mL, 3 mL)  
• The recommended dosage of Saxenda® is 3 .0mg daily.   
• The dose escalation below will be used.  
Week  Daily Dose  
[ADDRESS_856648]  3.0 mg 
 
Duration of 
administration  12 months  
Reference therapy  A placebo  
Statistical Methodology  Data will be analyz ed on an intention -to-treat basis. Our primary outcome 
(proportion of subjects losing at least 5% enrol lment body weight) will be 
assessed using Cochran -Mantel -Haenszel test after accounting for 
stratification variables .  The treatment groups will be further compared by 
[CONTACT_640196], using t -tests or Wilcoxon rank sum tests, (as 
appropriate) for continuous variables.  
152 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856649] effective treatment for obesity.  Of contemporary 157 
procedures,  Roux -en-Y Gastric By[CONTACT_6476] (RYGB) achieves the greatest weight loss - between one and two [ADDRESS_856650] over 30% total body weight. However,  the majority of 159 
patients regain weight follo wing a two -year nadir [1].  As time from surgery increases, so does the [ADDRESS_856651] loss 161 
of more than 50% pre -surgical excess body weight by [CONTACT_640197] [2].  Weight regain after 162 
RYGB is associated with the return of obesity -related comorbidies initially resolved following surgery 163 
[3]. Many patient s opt for revisional bariatric surgery  to address weight regain , but these procedures are 164 
often the source of significant morbi dity [4, 5] .  There are currently few non -surgical therapi[INVESTIGATOR_640184]  [ADDRESS_856652] use has been associated with weight loss in 170 
diabetic populations, with a meta -analysis finding an average loss of 3% total body weight with GLP -1 171 
receptor agonists v ersus  placebo  [6].  Further, several recent randomized trials have demonstrated the [ADDRESS_856653] completed a low calorie diet, W adden and colleagues 174 
reported 6.2% weight loss at 56 weeks v ersus 0.2% with placebo  [7].  Another recent trial in over 3 ,500 175 
overweight and obese patients randomized to liraglutide or placebo, in addition to lifestyle interventions, 176 
demonstrat ed 8.0% weight loss in the liraglutide arm versus 2.6% in the placeb o group [8].  Neither of the  [ADDRESS_856654] as an adjuvant to bariatric surgery for weight loss 179 
has shown promis e in animal mo dels, this therapy has yet to be tested in humans  [9].    [ADDRESS_856655] RYGB  who are e xperiencing weight regain at the  time of 188 
enrollment.  189 
1.2 Investigational Agent  190 
1.2.1 Name: [CONTACT_167818]®  (liraglutide (rDNA origin))  or matching placebo  191 
Saxenda® is a clear, colorless solution. Each 1 mL of Saxenda® solution contains 6 mg of liraglutide and 192 
the following inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; 193 
phenol, 5.5 mg; and water for injection. Each pre -filled pen contains a 3 mL solution of Saxenda® 194 
equivalent to 18 mg liraglutide (free -base, anhydrous).  [ADDRESS_856656] the same ingredients without the active ingredient ( 6 mg of liraglutide ). 197 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   8 
  198 
1.2.2  Class : Glucagon -like peptide -1 (GLP -1) receptor agonist  [ADDRESS_856657] to a reduced -calorie diet and increased physical activity for chronic weight management in adults 201 
with an initial BMI of ≥30kg/m2 (obese), or ≥27kg/m2 (overweight) in the presence of at least 1 weight - 202 
related comorbid condition (eg, HTN, type 2 diabetes mellitus [DM], dyslipi[INVESTIGATOR_035])  203 
1.2.4  Adult dosage  204 
Usual:  3.0mg daily; dose escalation should be used to reduce the likelihood of GI symptoms  205 
 206 
Dose Escalation:  207 
Week 1:  0.6mg/day  208 
Week 2:  1.2mg/day  209 
Week 3:  1.8mg/day  210 
Week 4:  2.4mg/day  [ADDRESS_856658]:  3.0mg/day  212 
May delay dose escalation for 1 additional week if unable to tolerate increased dose  213 
 214 
 215 
Missed Dose  216 
If a dose is miss ed, resume once -daily regimen with  next scheduled dose; do not take an extra 217 
dose or increase dose to make up for missed dose  218 
If >[ADDRESS_856659] dose, reinitiate at 0.6mg/day and retitrate following dose [ADDRESS_856660] in the abdomen, thigh, or upper arm; inj ection  site/timing can be changed without  224 
dose adjustment  225 
1.2.6 Pharmacokinetics  226 
Absorption  227 
• Bioavailability: subcutaneous : 55%  228 
• Tmax, subcuta neous : 8 to 12 hours; 11 hours (Saxenda ®)  229 
 230 
Distribution  231 
• Vd, subcutaneous : 13 L; 20 to 25 L (patients weighing 100 kg)  232 
• Vd, IV: 0.07 L/kg  233 
• Protein binding: Greater than 98%  234 
 235 
Metabolism  236 
• Metabolism: not significant  237 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   9 
  238 
Excretion  239 
• Fecal: 0% unchanged; 5% changed  240 
• Renal excretion: 0% unchanged; 6% changed  241 
• Total body clearance: 1.2 L/hr; 0.9 to 1.4 L/hr  242 
Elimination Half Life  243 
• 13 hours  244 
1.2.7 Mechanism of Action  245 
Liraglutide is an acylated human Glucagon -Like Peptide -1 (GLP -1) receptor agonist that acts to [ADDRESS_856661] of liraglutide is 250 
due to decreased calorie intake  251 
1.2.8 Contraindications  252 
• Hypersensitivity to liraglutide or any product component  253 
• Personal or family history of medullary thyroid carcinoma  254 
• Personal or family history of multiple endocrine neoplasia syndrome type 2  255 
• Pregnancy  256 
1.2.9 Limitations of Use  257 
• Saxenda® i s not indicated for the treatment of type 2 diabetes mellitus  258 
• Saxenda® and Victoza ® both contain the same active ingredient, liraglutide, and therefore 259 
should not be used together.  Saxenda® s hould not be used in combination with any other [ADDRESS_856662].  261 
• Saxenda® h as not been studied in patients taking insulin.  Saxenda® a nd insu lin should not 262 
be used together.  263 
• The effects of Saxenda® on cardiovascular morbidity and mortality have not established.  264 
• The safety and effectiveness of  Saxenda®  in combination with other products intended for [ADDRESS_856663] not been established.  267 
• Saxenda® h as not been studied in patients with a history of pancreatitis.  268 
1.2.10  Precautions  269 
• Black Box Warning  270 
• Risk of Thyroid C -cell Tumors  271 
o Liraglutide causes dose -dependent and treatment -duration -dependent thyroid C - 272 
cell tumors  at clinically relevant exposures in both genders of rats and mice .  It is 273 
unknown whether Saxenda® causes thyroid C -cell tumors, including medullary 274 
thyroid carcinoma  (MTC) , in humans, as the human relevan ce has not been 275 
determined.  276 
o Saxenda® is contraindicated in patients with a pe rsonal or family history of MTC 277 
and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).  278 
Counsel patients regarding the risk of MTC with use of Saxenda® and inf orm 279 
them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, 280 
dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using 281 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   10 
 thyroid ultrasound is of uncertain value for ea rly detection of MTC in patients 282 
treated with Saxend a®. 283 
 284 
• Warnings and Precautions  285 
o Acute Pancreatitis : Discontinue promptly if pancreatitis is suspected  since it may be 286 
life-threatening .  Do not restart if pancreatitis is confirmed.  287 
o Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, 288 
gallbladder studies are indicated.  289 
o Serious h ypoglycemia : Can  occur  when Saxenda® is used with an  insulin 290 
secretagogue  (eg, sulfony lureas).  Consider lowering the dose of anti -diabetic drugs 291 
to reduce the risk of hypoglycemia.  292 
o Heart rate increase: Monitor heart rate at regular intervals.  Discontinue Saxenda® if 293 
patients experience a sustained increase in resting heart rate.  294 
o Renal impairment: Has been reported postmarketing, usually in association with 295 
nausea, vomiting, diarrhea, or dehydration which may require hemodialysis .  Use 296 
caution when initiating or escalating doses of Saxenda® in patients with renal 297 
impairment.  298 
o Hypersensitivity reactions: Postmarketing reports of serious hypersensitivity 299 
reactions (e.g., anaphylactic reactions and angioedema).  Discontinue Saxenda® and [ADDRESS_856664] because it 303 
is unknown whether such patients will be predisposed to angioedema with Saxenda®. 304 
o Suicidal  behavior and Ideation: monitor for depression or suicidal thoughts.  305 
Discontinue Saxenda® if symptoms  develop.  306 
 307 
• Adverse Reaction  [ADDRESS_856665] common adverse reactions, reported in greater than or equal to 5% are: nausea, 309 
hypoglycemia, diarrhea, constipation, vomiting, headache, decreased appetite, 310 
dyspepsis, fatigue, dizziness, abdominal pain, and increased lipase.  311 
 312 
Pregnancy & Lactation  313 
 314 
U.S. Food and Drug Administration's Pregnancy Category:  Category X (All 315 
Trimesters)  316 
 317 
Crosses Placenta:  Unknown  318 
 319 
Clinical Management  320 
The brand name [CONTACT_167818] ®, which is indicated as an adjunct to diet and exercise for 321 
chronic weight management in overweight or  obese patients, has a pregnancy category of 322 
X. Saxenda ® is contraindicated in all pregnant women, including those who are already 323 
overweight or obese, because weight loss may result in fetal harm. If a woman becomes 324 
or wishes to become pregnant while on Saxenda ®, discontinue treatment.  325 
 326 
Literature Reports  327 
There are no adequate and well -controlled studies of liraglutide in pregnant women. In 328 
animal studies, teratogenicity occurred when female rats were given SC doses of 0.1, 329 
0.25, and 1 mg/kg/day (0.8, 3, and 11 times the human exposure at the maximu m 330 
recommended human dose (MRHD) based on plasma AUC) starting 2 weeks before 331 
mating through gestation day 17. Fetal abnormalities, kidney and blood vessel variations, 332 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   11 
 irregular skull ossification, and ossification were observed at all doses. In pregnant ra ts 333 
given the same doses from gestation day 6 through weaning or termination of nursing on 334 
lactation day 24, the majority had a slight delay in parturition. Group mean body weight 335 
of neonatal rats from the liraglutide -treated group was lower compared with c ontrols. 336 
Male offspring had bloody scabs and agitated behavior following maternal exposure to 1 337 
mg/kg/day. In pregnant rabbits, teratogenicity was seen following SC  doses of 0.01, 338 
0.025, and 0.05 mg/kg/day (less than the exposure at the MRHD at all doses) from 339 
gestation day 6 through day 18. Reduced fetal weight and dose -dependent major fetal 340 
abnormalities were reported at all doses. Malformations at the various doses included 341 
kidney and scapula (0.01 mg/kg), the eyes and forelimbs (0.01 mg/kg or greater), the 342 
brain, sacral vertebrae, major blood vessels, heart, and umbilicus (0.025 mg/kg), the 343 
sternum (0.025 mg/kg and greater), and parietal bones and major blood vessels (0.05 344 
mg/kg). Ossification, skeletal abnormalities, and dose -dependent minor skeletal 345 
variations were observed. Visceral abnormalities and bilobed or bifurcated gallbladder 346 
were seen in all dose groups.  347 
 348 
Breastfeeding  349 
Micromedex Lactation Rating: Infant risk cannot be ruled out.  350 
 351 
Available evidence and/or expert consensus is inconclusive or i s inadequate for [ADDRESS_856666] milk. In animal studies, 357 
liraglutide was excreted unchanged in the milk of lactating rats at concentrations 358 
approximately 50% of maternal plasma concentrations. Because data are limited and 359 
because of the tumorigenicity potential ev ident in animal studies, either discontinue 360 
nursing or discontinue liraglutide considering the importance of the drug to the mother.  361 
1.2.11  Storage & Stability  362 
 363 
Preparation  for administration  364 
• Inject liraglutide S C in the abdomen, thigh, or upper arm. Liraglutide may be 365 
administered any time of the day, independent of meals. Do not share pens with other 366 
patients.  367 
• To reduce the risk of IM injections and for better tolerance, use 4, 5, or 6 mm needles in 368 
all patients regardless of BMI or age. Injections should be giv en at a 90 degree angle to 369 
the skin surface. When injecting into limbs or a slim abdomen, use a lifted skin fold (4 370 
and 5 mm needles) or 45 degree angle (6 mm needle).  371 
 372 
Storage  373 
• Store unopened prefilled pens refrigerated, between 2 and 8 degrees C (36 and 46 degrees 374 
F).  375 
• Store opened pens up to 30 days at controlled room temperature, between 15 and 30 376 
degrees C (59 and 86 degrees F), or refrigerated, between 2 and 8 degrees C (36 and 46 377 
degrees F).  378 
• Protect from excessive heat and sunlight.  379 
• Avoid stori ng directly adjacent to cooling compartment in refrigerator.  380 
• Do not freeze or use a pen that has been frozen.  381 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856667] been noted to induce satiety and weight loss in multiple 383 
animal models. When given to bo th normal and obese rats, a significant reduction in food and 384 
water intake was noted in both groups, leading to significant weight loss of up to 15% of initial 385 
body weight  [10]. A similar study in obese mini -pi[INVESTIGATOR_640185] [ADDRESS_856668] on food intake  [11]. Candy -fed rats were also found to have normalized weight 387 
and fat levels after administration of lira glutide, reversing the effects of their diets  [12]. 388 
1.4 Clinical Data to Date  389 
(Please see Background and Significance  for additional relevant clinical data)  390 
 391 
Initial clinical data regarding the use of liraglutide in the treatment of obesity is from the 392 
NN8022 -1807  study conducted by [CONTACT_640198]  [13]. This was a double -blinded, placebo - 393 
controlled trial comparing liraglutide to Orlistat. Liraglutide was administered at 4 differe nt doses  394 
– 1.[ADDRESS_856669] significantly more 395 
weight than both the placebo and Orlistat group s.  Based on the success of this trial, participation 396 
in the study was extended to two years. Subjects rec eiving  the 2.4 mg/3.[ADDRESS_856670] on average 7.8 kg  [14]. 67% of patients completed two year follow -up. The  most 398 
common reasons for discontinuing the study were poor results (placebo arm) and nausea/vomiting 399 
(liraglutide arms).  400 
 401 
Further stu dies were then conducted in obe se, non -diabetic subjects. Van Can et a l. showed 402 
increased satiety, fullness, and decreased gastric emptying using both liraglutide 1.8 mg and 3.0 403 
mg dosing compared to placebo  [15]. Thi s suggested that liraglutide -induced weight loss was 404 
secondary to reduced appetite and intake rather than increased energy expenditure. Pi-Sunyer et 405 
al. conducted a recent trial in which over 3 ,500 overweight and obese patients were randomized 406 
to liragluti de or placebo, in addition to lifestyle interventions . These authors  demonstrated 8.0% 407 
total body weight loss in the liraglutide arm , versus 2.6% in the placebo group  [8]. [ADDRESS_856671] as an adjuvant to 411 
bariatri c surgery for weight loss has shown promise in animal models, this therapy has yet to be 412 
rigorously tested  in humans  [9]. 413 
1.5 Dose Rationale  414 
The dosage chosen for this study is 3 mg daily, injected subcutaneously. Dosages are steadily 415 
escalated over a 5 week period, from 0.6 mg/day to 3 .0 mg/day. Route of administration is [ADDRESS_856672] percentage of weight loss in patients, compared to doses of 1.2, 1.8, and 2.4 419 
mg, without increased adverse events  [13]. Subsequent studies have also used the 3 .0 mg dosing 420 
and shown comparable weight loss effects  [7, 8] . The 3 .0 mg dosing is currently approved by [CONTACT_941] 421 
FDA for the indication of weight loss in overweight and obese individuals. The d osage regimen 422 
and period  in this study  are also based on these prior studies. Liraglutide is a once -daily dosed 423 
medicine, with a half -life of 11 -12 hours  [16].  424 
1.6 Research Risks & Benefits  425 
1.6.1 Risk of Study Drug  426 
• Nausea (39.3%)  427 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   13 
 • Diarrhea (20.9%)  428 
• Hypoglycemia in Type 2 DM (23.0%)  429 
• Constipation (19.4%)  430 
• Vomiting  (15.7%)  431 
• Headache (13.6%)  432 
• Decreased appetite (10.0%)  433 
• Dyspepsia  (9.6%)  434 
• Fatigue (7.5%)  435 
• Dizziness (6.9%)  436 
• Abdominal pain  (5.4%)  437 
• Increased lipase (5.3%)  438 
• Upper abdominal pain  (5.1%)  439 
• Gastroesophageal reflux disease (4.7%)  440 
• Gastroenteritis (4.7%)  441 
• Abdominal distension  (4.5%)  442 
• Eructation  (4.5%)  443 
• Urinary tract inf ection (4.3%)  444 
• Flatulence (4.0%)  445 
• Viral gastroenteritis (2.8%)  446 
• Injection site erythema (2.5%)  447 
• Injection site reaction (2.5%)  448 
• Insomnia (2.4%)  449 
• Dry mouth  (2.3%)  450 
• Asthenia (2.1%)  451 
• Anxiety (1.6%)  452 
• Cholelithiasis (1.5%)  453 
• Hypotension (1.1%)  454 
• Urticaria (0.7%)  455 
• Breast cancer (0.6%)  456 
• Cholecystitis (0.6%)  457 
• Colorectal neoplasms (0.5%)  458 
• Pancreatitis (0.3%)  459 
• Cardiac conduction disorder (0.3%)  460 
• Suicidal thoughts (0.2%)  461 
• Papi[INVESTIGATOR_243703] (0.2%)  462 
• Angioedema and anaphylactic reaction  (reported, but percentage unknown ) 463 
• C-cell hyperplasia of thyroid  (potential risk)  464 
• Medullary thyroid carcinoma  (potential risk)  465 
 466 
Measures to minimize the risks  467 
• Dose escalation is  used to reduce the likelihood of GI symptoms  468 
• All contraindications include d in exclusion criteria  469 
• Lipase  and Amylase  included in study blood work  470 
• Monitor heart rate during study visits  471 
• Monitor depression during study visits  472 
• Monitor fasting glucose at each study visit for hypoglycemia and lower th e dose of 473 
anti-diabetic drugs for patients taking  an insulin secretagogue (eg, sulfonylureas)  if 474 
fasting glucose is ≤70 m/dL .  If hypo glycemia continues, the insulin secretagogue  475 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856673]’s primary 476 
physician/en docrinologist.  477 
• Patients taking  an insulin s ecretagogue (eg, sulfonylureas) will be  inform ed of the  [ADDRESS_856674] ed to notify the  investigators of  any symptoms of hypoglycemia . 480 
• If the subject is a female of childbearing potential (sexually active and not sterile nor [ADDRESS_856675] 1 year), have a  negative pregnancy tes t within 4  weeks 482 
prior to study  commencement , and then at 3, 6, and 9 months.  483 
• Use of reliable co ntraception will be assessed during the study period.  484 
• DSMB reviews all AEs including SAEs and provides the appropriate [ADDRESS_856676] udy are to assess the efficacy of liraglutide in improving 497 
cardiometabolic risk profile (as indicated by [CONTACT_640199][INVESTIGATOR_805], HbA1c, and waist circumference) and quality 498 
of life (as assessed by [CONTACT_205441] -9 (Patient Health Questionnair e), versus placeb o in patients at least 18 499 
months following  RYGB who  are experiencing weight regain.  as well as the safety of liraglutide in this 500 
patient population.  501 
3 Study Design  502 
3.1 Research Design and Methods  503 
The specific aims of this proposal are:  504 
• To evaluate the effects of liraglutide on body weight loss in patients who are experiencing weight 505 
regain following RYGB.  506 
o We will perform a randomized, double -blinded, placebo -controlle d trial of liraglutide  507 
versus placebo over a follow -up period of 12 mon ths.  508 
▪ We hypothesize  that the liraglutide group will  contain a significantly greater [ADDRESS_856677] 5% loss of pre -randomization body 510 
weight at 12 months, than the placebo group.   511 
• To evaluate the effects of liraglutide on cardio metabolic risk and quality of life in patients who 512 
are experiencing weight regain  following RYGB.  513 
o We will perform a randomized, double -blinded, placebo -controlled trial of liraglutide  514 
versus placebo over a follow -up period of 12 months.  515 
▪ We hypothesize tha t the liraglutide group will demonstrate greater improvement 516 
in cardiovascular risk profile (as assessed by [CONTACT_640199][INVESTIGATOR_805], HbA1c, and waist 517 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   15 
 circumference) and quality of life (as assessed by [CONTACT_127659] -9) at 12 months, than 518 
the placebo group.   519 
• To evaluate the  safety of liraglutide in post -RYGB subjects.  520 
o We will monitor adverse events, bl ood counts and serum chemistries  in subjects 521 
receiving liraglutide or placebo over a period of 12 months . 522 
▪ We hypothesize that the liraglutide group will exhibit more frequent 523 
hypoglycemia and elevations in lipase and amylase, but that these epi[INVESTIGATOR_640186] 524 
be clinically insignificant.  525 
• To evaluate the changes in obesity -related comorbid conditions  in patients who are experiencing 526 
weight regain  following RYGB.  527 
o We will monitor obesity -related comorbid conditions  in subjects receiving liraglutide or 528 
placebo over a period of 12 months.   529 
▪ We hypothesize that the liraglutide group will exhibit improvement s in obesity- 530 
related comorbid conditions  (hyperglycemia , hyper lipi[INVESTIGATOR_035], blood pressure , and 531 
obstructive sleep apnea ) at 12 months, than the placebo group.   532 
3.2 Endpoints  533 
• Primary Endpoint:  Proportion  of subjects losing at least 5% of enrol lment body weight  at 12 months.  534 
• Secondary Endpoints:  Fasting serum glucose, HbA1c , LDL -cholesterol, HDL -cholesterol, [ADDRESS_856678] circumference , blood pressure , STOP -BANG score , PHQ -9 536 
• Primary and secondary endpoints will be assessed at clinic visits  prior to randomization and  at 3, 6, [ADDRESS_856679] study drug  administration . 538 
3.3 Study Type  539 
Randomized, single -center, double -blind, placebo -controlled study with two arms.  Randomization will 540 
be 2:1 (drug:placebo) with stratification by [CONTACT_640200]-operative  TBWL (25%, 25 – 49.9%).   [ADDRESS_856680] -RYGB population.  2:[ADDRESS_856681]-RYGB patients in our retrospective database , and that recent data from our program suggests 549 
that 80 % of patients at least [ADDRESS_856682] RYGB exhibit regain of ≥10%  of maximum post - 550 
surgical TBWL  – our program has a potential subject pool of 560.  We estimate that at least 50% of [ADDRESS_856683] 5% of enrol lment body weight  at 12 months . 557 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856684] treatment administration . 563 
3.7 Primary Safety Endpoints  564 
The primary safety endpoint is the  percentage of patients who are experiencing AEs during  12 months  of 565 
the trial .   566 
3.7.1 Assessments for Safety  567 
• BMP  (Fasting glucose)  568 
• Amylase  569 
• Lipase  570 
• Pregnancy Test  (Only applicable for women of childbearing potential)  571 
• Heart Rate  572 
• PHQ -9 573 
• Current medication list review   574 
• Adverse event assessment  including symptomatic hypoglycaemia for Type [ADDRESS_856685] Selection and Withdrawal  576 
4.1 Number of the subjects: [ADDRESS_856686] aw or become ineligible.  578 
4.2 Rationale for study population  579 
The Roux -en-Y gastric by[CONTACT_6476] (RYGB) is not only the most common bariatric procedure, but also the [ADDRESS_856687] to which all others are compared. The average weight loss after RYGB is approximately 581 
35% total body weight. . However, the majority of  patients who undergo this procedure experience weight [ADDRESS_856688] to the long -term treatment plan in patients 587 
who experience weight regain after RYGB.  588 
4.3 Inclusion Criteria  589 
• >18 years who are  deemed medically stable  590 
• ≥[ADDRESS_856689] RYGB at time of enrollment 591 
• BMI of ≥30 kg/m2 or ≥ 27 kg/m2 in the presence of at least one weight -related comorbid 592 
condition  593 
• Regain of ≥10%  of maximum TBWL post -RYGB   594 
• Ability to provide informed consent before any trial -related activities  595 
• Express willingness to provide signed informed consent and follow protocol requirements  596 
4.4 Exclusion Criteria  597 
• BMI of >45 kg/m2 598 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   17 
 • Pregnancy  at time of enrollment  599 
• Intention of becoming p regnant  or breast feeding  in the next 12 months  600 
• Females of childbearing potential who are not using adequate contraceptive methods  601 
• Presence of acute psychiatric problems or immaturity which would compromise coop eration with 602 
the study protocol  603 
• Presence of biliary disease  604 
• Known or suspected allergy to li raglutide or any product components  605 
• Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia 606 
syndrome type 2  607 
• History of pancreatitis  608 
• History of alcoholism  609 
• History of Type 1 DM (Diabetes Mellitus)  610 
• History of previous bariat ric surgery other than RYGB except h/o LAGB and band removal.  611 
• >[ADDRESS_856690] RYGB  612 
• < 25% TBWL at post -RYGB weight nadir  613 
• >50% post -operative TBWL at time of screening  614 
• Simultaneous u se of  any weight loss medications  615 
• Use of insulin at the  time of  enrollment  616 
• Current use of any GLP -[ADDRESS_856691] medication  617 
• History  of taking any GLP -[ADDRESS_856692] medication  618 
• Participation in another ongoing  clinical study  619 
• Conditions that, in the opi[INVESTIGATOR_14371], may jeopardize the patient’s wel l- 620 
being and/or the soundness of this clinical study  [ADDRESS_856693] recruitment and screening will be conducted by [CONTACT_40193] s of the research team.   624 
• Potentially eligible p atients  will be identified  from the investigators’  confidential clinical registry 625 
and referring physicians including self -referring patients  626 
• If necessary, p otential eligible patients will be recruited via online platform (i.e. Obesity Help, 627 
Bariatric Pal, Faceboo k), newspaper advertisement s, study  fliers , or study brochures  628 
• In addition to these methods, subjects may be recruited through MyChart (if indicated they are 629 
willing to be contact[CONTACT_640201]), DataCore, i2b2  or iConnect . 630 
• DataCore may be used as a  recruitment method to request reports from Epic, NYU’s electronic [ADDRESS_856694] system.  The following data points will be requested: medical record number 632 
(MRN), DOB (to assess current age), diagnosis, gender, and living status (alive). Patients will be [ADDRESS_856695] - 644 
[EMAIL_2365] or 1 -[PHONE_2698]. The amount of times EPIC will be searched over the 645 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856696] patients 646 
who are open for recruitment (based on th eir choice listed in Epic) directly.  647 
• Due to the time -sensitive inclusion criteria for this study (surgery between 18 months and 10 648 
years), eligible participants may not have a treating physician on record in Epic as they may not [ADDRESS_856697] information if there are any concerns.  653 
If there is no primary care physician listed, this will be noted in the patient’s research record; 654 
however they still may be contact[CONTACT_94093] .  655 
• The following roles will have access to the EPIC search results: Principle Investigator, Research  656 
Coordinator and Study Team Member . 657 
• The research staff will contact [CONTACT_640202] [ADDRESS_856698] information on the online websites.  660 
• Study e ligibility  will be determined  by [CONTACT_640203] 661 
exclusion criteria  662 
• Patient s will be o ffered the opportunity to participate in this study via telephone , email, mail  663 
or/and in-person conversation in a private room to protect patient’s privacy.  M ore privacy will be 664 
provided if required or demanded  665 
• A verbal explanation of the study will be given followed by a written consent form  666 
• For any patient who might be illiterate, consent  forms will be read to him or her and witnessed by [ADDRESS_856699] pa rty Patients will be provided with ample time and opportunity to ask about 668 
the details of the study, and decide whether or not they want to participate, and patient informed 669 
consent will be obtained, prior to any study specific procedures  670 
• No screening test s/procedures  will be performed before a subject signs the consent form  [ADDRESS_856700] also give Authorizati on for Use and Release of Health and 674 
Research Study Information and other written documentation in accordance with the relevant country and 675 
local privacy requirements (where applicable) prior to any study -related procedures or change in 676 
treatment.  677 
 678 
The In vestigator or his/her authorized designee conducts the informed consent ( IC) discussion and will [ADDRESS_856701]’s medical records the acquisition of IC and the subject’s agreement.  The IC shall [ADDRESS_856702]’s decision to participate throughout the [ADDRESS_856703] throughout the study. The Investigator will ensure  that important new 686 
information is p rovided to new or existing subjects throughout the study.  687 
4.6 Early Withdrawal of Subjects  688 
4.6.1 When and How to Withdraw Subjects  689 
• If a subject is  not able to  tolerate the study drug , the subject  will be removed from the study.  690 
• If a subject decide s to withdraw from the study, the subject will be removed from the study.  691 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   19 
 • If the PI [INVESTIGATOR_640187]  a subject’s  best interest to discontinue participation, the subject will 692 
be removed from all remaining study requirements.  693 
• A subject may be withdrawn from the study at the discretion of the PI [INVESTIGATOR_378028] a safety concern or [ADDRESS_856704]’s permission to record  this information . [ADDRESS_856705]-to-follow -up 709 
• A minimum of [ADDRESS_856706]-to-follow -up. 711 
 712 
5 Study Drug  713 
5.1 Description  714 
Saxenda ® or matching placebo  715 
• Subcutaneous Solution: 6 mg/ml  716 
• Solution for subcutaneous injection, pre -filled, multi -dose pen that delivers doses of 0.6mg, 1.2 717 
mg, 1.8  mg, 2.4 mg or 3 .0 mg (6mg/mL, 3mL)  718 
5.2 Treatment Regimen  719 
Dose:  720 
• Recommended dose of S axenda ® or matching placebo  is 3.0 mg daily  721 
• Administer at any time of the day, withou t regard to the timing of meals  722 
 723 
Dose escalation should be used to reduce the likelihood of GI symptoms  724 
• Week  1: 0.6mg/day  725 
Week 2:  1.2mg/day  726 
Week 3:  1.8mg/day  727 
Week 4:  2.4mg/day  [ADDRESS_856707]:  3.0mg/day  729 
• May delay dose escalation for 1 additional week if unable to tolerate increased dose  730 
• Discontinue  if patien t is unable to tolerate the study drug  for any reason  731 
 732 
Route:  733 
• Inject subcutaneously in the abdomen, thigh or upper arm.  734 
• The injection site and timing can be changed without dose adjustment.  735 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856708] Compliance Monitoring  736 
• The study drug will be dispensed to each subject at study visit s (baseline, 3, 6, 9 months) and will 737 
be recorded by [CONTACT_640204] .   738 
• The subjects  are required to return used  pens when receiving n ew drug and the number of used 739 
pens returned will be recorded by [CONTACT_640205].  740 
• Subjects are required to bring a daily study drug administration log to  3, 6, 9, and 12 months 741 
study visit s. 742 
• Subjects who are not compliant wit h administrating the study drug  ≥ 30 days will be withdrawn 743 
from the study.  744 
5.4 Concomitant Therapy  745 
• Avoi d use with insulin  746 
• Avoid use with other glucagon -like peptide -1 receptor agonists  747 
• Advise to take daily post RYGB supplements which include multivitamin  with copper , calcium, 748 
vitamin D, iron, and vitamin B12.   749 
5.5 Receiving, Storage, Dispensing and Return  750 
5.5.1 Receipt of Drug Supplies  751 
• Upon receipt of the study treatment supplies, an inventory  will be performed and a drug receipt 752 
log filled out and signed by [CONTACT_17247].   753 
• The designated study staff  will counts  and verifies that the shipment contains all the items noted 754 
in the shipment inventory.   755 
• Any damaged or unusable study drug in a given shipment (active drug or comparator) will be 756 
documented in the study files.   757 
• The investigator will notify Novo Nordisk  of any dama ged or unusable study drug  that was 758 
supplied to the investigator’s site.  759 
5.5.2 Storage  760 
• All study drugs will be stored at the NYU LMC  investigational pharmacy and distributed by [CONTACT_941] [ADDRESS_856709] .  762 
• Store unopened prefilled pens refrigerated, between 2 and 8 degrees C (36 and 46 degrees F).  763 
• Store opened pens up to 30 days at controlled room temperature, between 15 and 30 degrees C 764 
(59 and 86 degrees F), or refrigerated, between 2 and 8 de grees C (36 and 46 degrees F) and [ADDRESS_856710] from excessive heat and sunlight.  766 
• Avoid storing directly adjacent to cooling compartment in refrigerator.  767 
• Do not freeze or use a pen that has been frozen.  768 
5.6 Method for Assigning Subjects to Treatment Groups and Dispensing 769 
of Study Drug  770 
5.6.1 Randomization Process  771 
Eligible subjects will be randomized to one of the two treatment group s in a 2:1 ratio to receive either 772 
study drug (Liraglutide  (rDNA origin) injection, 3 x Saxenda® pen, NDC 0169 -2800 -13) or matching [ADDRESS_856711] -operative TBWL (<25%, 25 – 49.9%) .  Stratified [ADDRESS_856712]  who will then 775 
be able to distribute the study drug/placebo as patients are enrolled, and the rem ainder of the study staff 776 
will be blinded.  777 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856713] at study visit s (baseline, 3, 6, 9 months) upon returning 779 
the used  pens and the compliance with study drug administration  will be recorded by [CONTACT_251274] 780 
pharmacy  and study team .   781 
 782 
Study drug reconciliation will be performed to document drug assigned, drug consumed, and drug 783 
remaining.  This reconciliation will be logged on the drug reconciliation form, and signe d and dated by 784 
the study team.  785 
5.6.3 Return or Destruction of Study Drug  786 
At the completion of the study, there will be a final reconciliation of drug shipped, drug consumed, and 787 
drug remaining.  This reconciliation will be logged on the drug reconciliation form, signed and dated.  788 
Any discrepancies noted will be investigated, resolved, and documented prior to return or destruction of 789 
unused study drug.  Drug destroyed on site will be documented in the study files.  790 
6 Study Procedures  791 
 792 
Visit Number  1   2   3   4   5 
 Baseline  1M 2M 3 
months  4M 5M 6 
months  7M 8M 9 
months  10M  11M  12 
months  
Visit window  0-4 wks 
prior to 
the 
treatment    
± 4 wks    
± 4 wks    
± 4 wks    
± [ADDRESS_856714] & 
Neck 
Circumference  X   
X   
X   
X   
X 
Height  X             
Medications  X   X   X   X   X 
Blood 
Pregnancy 
Test (Beta 
Quantitative 
HCG)  (Only 
applicable 
for women of 
childbearing 
potential)  X   
X   
X   
X   
X 
1BMP, 
HbA1c, 1Lipid 
profile, 
Amylase, 
Lipase  X   
X   
X   
X   
X 
Additional 
plasma and X      X      X 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856715]  X   
X   
X   
X   
X 
Body 
Composition  X   X   X   X   X 
Comorbidities:  
Diabetes, 
Hypertension, 
STOP -BANG  X   
X   
X   
X   
X 
2AEs X X X X X X X X X X X X X 
Study 
Medication 
Compliance 
Phone call   X X  X X  X X  X X  
1. Fasting is required  793 
2. Ask about hypoglycemia symptoms  for patients  with Type 2 DM  794 
6.1 Visit 1  (Baseline/Pre -Treatment ) 795 
6.1.1 Screening and Enrollment  796 
Patients meeting all inclusion and no exclusion criteria will be offered the opportunity to participate in 797 
this study. Patient informed consent will be obtained prior to any study specific procedures and patients 798 
will be provided with ample time and opportunity to ask about the details of the study, and decide 799 
whether or not to participate.  800 
6.1.2 Medical History  801 
A full medical history will be taken during t he baseline visit. Medical history includes  previous bariatric 802 
and non -bariatric surger ies, and recent &  lifetime health history.   803 
6.1.3 Demographics  804 
At baseline, the following demographic data will be collected and recorded: gender, date of birth, and 805 
race/et hnicity.  806 
6.1.4 Physical Examination  / Clinical Assessment  807 
During the baseline and all in -office follow -up visits, a physical examination will be performed and the 808 
following data will be collected and recorded:  809 
• Blood pressure  810 
• Heart rate  811 
• Height (only at baseline)  812 
• Weight  813 
• Waist and neck  circumference  814 
• Medications  815 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   23 
 6.1.5 Diet and Physical Activity Counseling  816 
• Initial nutritional assessment  by [CONTACT_135569] (Registered Dietician)  817 
• 24 hr diet recall (see attachment)  818 
• Body composition (Basic metabolic rate, % total body fat, % body water weight, muscle mass 819 
weight)  820 
6.1.6 Comorbidities Assessment  821 
Comorbidity status will be assessed at baseline.  The following co -morbid conditions will be assessed:  822 
diabetes, hypertension, and STOP -BANG score .  823 
 824 
Diabetes Scale  825 
Score  Description  
0 Fasting blood glucose (<100 mg/dL)  
1 Fasting blood glucose ≥100-125 mg/dL  or diabetes,  no medications  
2 Fasting blood glucose ≥126 mg/dL or diabetes treated with medication (oral and/or 
injectable)  
Number of medications: ______  826 
Hypertension Scale  827 
 Description  
0 Normal BP, no indication of hypertension (BP below 120/80 mmHg), no medication  
1 Prehypertension (systolic BP 120 -139 or diastolic BP 80 -89 mmHg), no medication  
2 Stage 1 hypertension (systolic BP 140 -159 or diastolic BP 90 -99 mmHg) or 
hypertension controlled with single medication  
3 Stage 2 hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥  100 mmHg) or 
hypertension controlled with multiple medications  
4 Hypertension poorly controlled despi[INVESTIGATOR_640188]  
 828 
 STOP -BANG score : _____  829 
1. Do you snore loudly (louder than talking or loud enough to be heard 
through closed doors)?  Yes No 
2. Do you often feel tired, fatigued, or sleepy during daytime?  Yes No 
3. Has anyone observed you stop breathing during your sleep?  Yes No 
4. Do you have or are you being treated for high blood pressure?  Yes No 
5. BMI >30kg/m2  Yes No 
6. Age >50  Yes No 
7. Neck circumference >16 inches  Yes No 
8. Male  Yes No 
 830 
6.1.7 Blood work  (total 25 ml blood collection)  831 
• Blood Pregnancy  (Total Beta Quantitative HCG)  (Only applicable for women of childbearing 832 
potential)  833 
• Fasting BMP  834 
• HbA1c  835 
• Lipid profile  836 
• Amylase  837 
• Lipase  838 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   24 
 • Additional  [ADDRESS_856716] -RYGB patients . 840 
o Collecting additional blood for future analysis is mandatory because it is imperative that the stored 841 
sample be used for continued analyses as new scientific discoveries are available and for retesting 842 
during the course of the study if necessary.  843 
o Samples will be stored in the Bell Vascular Biology Research Program (NYU Smilow 7th floor) [ADDRESS_856717]’s identifiers . The master list linking names to code [ADDRESS_856718].  856 
 857 
6.1.8 Questionnaires  858 
• PHQ -9 (see attachment)  859 
• IPAQ (see attachment)  860 
 861 
6.2 Visit 2 , 3, 4 (Post -treatment)  862 
6.2.1 Physical Examination  / Clinical Assessment  863 
During the baseline and all in -office follow -up visits, a physical examination will be performed and the 864 
following data will be collected and recorded:  865 
• Blood pressure  866 
• Heart Rate  867 
• Weight  868 
• Waist and neck  circumference  869 
• Medications  870 
6.2.2 Diet and Physical Activity Counseling  871 
• Follow up diet and physical activity counseling  by [CONTACT_135569]  872 
• Collection of diet and exercise diaries  (see attachment ) 873 
• Body composition (Basic metabolic rate, % total body fat, % body water weight, muscle mass 874 
weight)  875 
6.2.3 Comorbidities Assessment  876 
The following co -morbid conditions will be assessed: diabetes,  hypertension,  and STOP -BANG score  at 877 
the 3, 6, 9 and 12  month visits.  878 
6.2.4 Blood work   879 
Total 10 ml blood collection for visit 2 and 4  880 
Total 25 ml blood collection for visit 3 and 5  881 
• Blood Pregnancy  (Total Beta Quantitative HCG)  (Only applicable for women of childbearing 882 
potential)  883 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   25 
 • BMP  884 
• HbA1c  885 
• Lipid profile  886 
• Amylase  887 
• Lipase  888 
• Additional  [ADDRESS_856719] -RYGB patients  (6 and 12 months only) . 890 
6.2.5 Questionnaires  891 
• PHQ -9  892 
• IPAQ  [ADDRESS_856720] at 1, 2, 4, 5, 7, 8, 10, and 11 months to review medication compliance and 898 
adverse events.   899 
7 Statistical Plan  900 
7.1 Sample Size Determination  901 
We intend to recruit 132 subjects.  A recent study o f liraglutide versus placebo in subjects weighing 106.2 902 
+/- 21.1 kg (BMI 38.2 ± 6.4) at baseline demonstrated that nearly 2/[ADDRESS_856721] 5% of enrollment body weight, vs. approximately 1/[ADDRESS_856722] an absolute difference of 36.1% in the proportion [ADDRESS_856723] 5% of enrollment body weight in the liraglutide (expected proportion 63.2%) 906 
and placebo arms (expected prop ortion 27.1%), with an alpha of 0.05 and beta of 0.1, we will require a 907 
sample size of 99 (2x liraglutide:1x placebo).  In order to account for an estimated loss -to-follow -up of 908 
25%, we increase the sample size to 132.  909 
7.2 Statistical Methods  910 
Data will be anal ysed on an intention -to-treat basis. Missing values  will be  assessed for patterns and 911 
imputed using a multiple imputation  method for measurements made after baseline. Patient demographics 912 
will be summarized by [CONTACT_1570].  Categorical variables will be presented as proportions, normally 913 
distributed continuous variables will be presented as mean ± standard deviation, and skewed continuous 914 
variables will be presented  as median [interquartile range]. Our primary outcome ( proportion  of subjects [ADDRESS_856724] 5% enrol lment body weight) will be assessed using Cochran -Mantel -Haenszel test after 916 
accounting for stratification variables .  The treatment groups will be furthe r compared by [CONTACT_640206] 917 
outcomes, using t -tests or Wilcoxon rank sum tests, (as appropriate) for continuous variables. Prior to 918 
analysis, n on-normally distributed continuous data will be categorized using quartiles or using an 919 
appropriate transformation me thod (e.g. log-transformed ).   [ADDRESS_856725] -intervention measurements differs from the baseline 923 
measurement. Change in continuous secondary outcome variables will be compared between treatment 924 
groups using inde pendent samples t -tests.  An AN COVA model including stratification variables (gender, [ADDRESS_856726] -operative weight loss) will be used to assess changes in these secondary outcomes.  These 926 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856727] Population(s) for Analysis  929 
Primary and secondary analyses will be performed in the all -treated population.  930 
7.4 Interim Analysis  931 
Given the limited duration of the study, we do not plan interim analyses of efficacy parameters.   932 
8 Safety and Adverse Events  933 
8.1 Definitions  934 
8.1.1 Unanticipated Problems Involving Risk to Subjects or Others  935 
Any incident, experience, or outcome that meets all of the following criteria:  936 
• Unexpected in nature, severity, or frequency   937 
• Related or possibly related to participation in the research (i.e. possibly related means there is a [ADDRESS_856728] been caused by [CONTACT_941] 939 
procedures invol ved in the research)  940 
• Suggests that the research places subjects or others at greater risk of harm (including physical, 941 
psychological, economic, or social harm).  942 
8.1.2 Adverse Event  943 
An adverse event  (AE)  is any symptom, sign, illness or experience that develops o r worsens in severity 944 
during the course of the study.  Intercurrent illnesses or injuries should be regarded as adverse events.  945 
Abnormal results of diagnostic procedures are considered to be adverse events if the abnormality:  946 
• results in study withdrawal  947 
• is associated with a serious adverse event  948 
• is associated with clinical signs or symptoms  949 
• leads to additional treatment or to further diagnostic tests  950 
• is considered by [CONTACT_1372]  951 
[IP_ADDRESS]  Expected Adverse Events  related to study d rug 952 
• Nausea (39.3%)  953 
• Diarrhea (20.9%)  954 
• Hypoglycemia in Type 2 DM (23.0%)  955 
• Constipation (19.4%)  956 
• Vomiting (15.7%)  957 
• Headache (13.6%)  958 
• Decreased appetite (10.0%)  959 
• Dyspepsia (9.6%)  960 
• Fatigue (7.5%)  961 
• Dizziness (6.9%)  962 
• Abdominal pain (5.4%)  963 
• Increased lipase (5.3%)  964 
• Upper abdominal pain (5.1%)  965 
• Gastroesophageal reflux disease (4.7%)  966 
• Gastroenteritis (4.7%)  967 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   27 
 • Abdominal distension (4.5%)  968 
• Eructation (4.5%)  969 
• Urinary tract infection (4.3%)  970 
• Flatulence (4.0%)  971 
• Viral gastroenteritis (2.8%)  972 
• Injection site erythema (2.5%)  973 
• Injection s ite reaction (2.5%)  974 
• Insomnia (2.4%)  975 
• Dry mouth (2.3%)  976 
• Asthenia (2.1%)  977 
• Anxiety (1.6%)  978 
• Cholelithiasis (1.5%)  979 
• Hypotension (1.1%)  980 
• Urticaria (0.7%)  981 
• Breast cancer (0.6%)  982 
• Cholecystitis (0.6%)  983 
• Colorectal neoplasms (0.5%)  984 
• Pancreatitis (0.3%)  985 
• Cardiac conduction dis order (0.3%)  986 
• Suicidal thoughts (0.2%)  987 
• Papi[INVESTIGATOR_243703] (0.2%)  988 
• Angio edema and anaphylactic reaction (reported, but percentage unknown)  989 
• C-cell hyperplasia of thyroid (potential risk)  990 
• Medullary thyroid carcinoma (potential risk)  991 
8.1.3 Serious Adverse Event  992 
Adverse events are classified as serious or non -serious.  A serious adverse event  is any AE that is:  993 
• fatal 994 
• life-threatening  995 
• requires or prolongs hospi[INVESTIGATOR_4408]  996 
• results in persistent or significant disability or incapacity  997 
• a congenital anomaly or birth defect  998 
• suspi[INVESTIGATOR_508454]  999 
• an important medical event  [ADDRESS_856729], and may require intervention to prevent one of 1003  
the other serious outcomes noted above.  For example, drug overdose or abuse, a seizure that did not 1004  
result in in -patient hospi[INVESTIGATOR_059], or intensive treatment of bronchospasm in an emergen cy department 1005  
would typi[INVESTIGATOR_15355].  1006  
 1007  
All adverse events that do not meet any of the criteria for serious should be regarded as non-serious 1008  
adverse events .  1009  
8.1.4 Serious Adverse Drug Reaction (SADR)  1010  
An adverse drug reaction (ADR) is an adverse event for which a causal relationship (Possible/Probable 1011  
relation) between the study drug and the occurrence of the event is suspected. The ADR should be 1012  
classified as serious  if it meets one or more of the seriousness criteria.  1013  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   28 
 [IP_ADDRESS]  Reported serious adverse events/reactions related to study drug  1014  
• Potential Risk of Thyroid C -Cell Tumors  1015  
• Acute Pancreatitis  1016  
• Acute Gallbladder Disease  1017  
• Risk for Hypoglycemia with Concomitant Use of Anti -Diabetic Therapy  1018  
• Heart Rate Increase  1019  
• Renal Impairment  1020  
• Hypersensitivity Reactions  1021  
• Suicidal Behavior and Ideation  1022  
8.1.5 Severity Assessment Definitions  1023  
• Mild: Transient symptoms, no interference with the subje ct’s daily activities  1024  
• Moderate: Marked symptoms, moderate interference with the subject’s daily activities  1025  
• Severe: Considerable interference with the subject’s daily activities, unacceptable  1026  
8.1.6 Relationship to Study Drug  Assessment Definitions  1027  
• Probable: Good reasons and sufficient documentation to assume a causal relationship  1028  
• Possible: A causal relationship is conceivable and cannot be dismissed  1029  
• Unlikely: The event is most likely related to an etiology other than the trial product  1030  
8.1.7 Outcome Categories and Definitions  1031  
• Recovered: Fully recovered or by [CONTACT_57676] [ADDRESS_856730] signed the informed 1033  
consent  1034  
• Recovering: The condition is improving and the sub ject is expected to recover from the event. [ADDRESS_856731] has completed the trial  1036  
• Recovered with sequelae: As a result of the AE, the subj ect suffered persistent and  significant 1037  
disability/incapacity (e.g. became blind, dea f, paralysed). Any AE recovered with sequelae 1038  
should be rated as an SAE  1039  
• Not recovered  1040  
• Fatal  1041  
• Unknown  [ADDRESS_856732] seek information on adverse events by [CONTACT_203935] 1049  
questioning and, as appropriate, by [CONTACT_5148].  Information on all adverse events should be recorded 1050  
immediately in the source document, and also in the appropriate adverse event module of the case repo rt 1051  
form (CRF).  All clearly related signs, symptoms, and abnormal diagnostic procedures results should [ADDRESS_856733] administration of study treatment.   1057  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856734] be followed up to determine the final outcome.  Any serious adverse event that occurs after 1062  
the study period and is considered to be possibly related to the study treatment or study participation 1063  
should be recorded and reported immediately.  1064  
[IP_ADDRESS]  Preexisting Condition  1065  
A preexisting condition is one that is present at the screening of the study.  A preexisting condition should 1066  
be recorded as an adverse event if the frequency, intensity, or the character of the condition worsens 1067  
during the study period.  1068  
[IP_ADDRESS]  General Physical Examination Findings  1069  
At screening, any clinically significant abnormality should be recorded as a preexisting condition.  At the 1070  
end of the study, any new clinically significant f indings/abnormalities that meet the definition of an [ADDRESS_856735] also be recorded and documented as an adverse event.   1072  
[IP_ADDRESS]  Abnormal Laboratory Values  1073  
A clinical laboratory abnormality should be documented as an adverse event if any one of the following  1074  
conditions is met:   1075  
• The laboratory abnormality is not otherwise refuted by a repeat test to confirm the abnormality  1076  
• The abnormality suggests a disease and/or organ toxicity  1077  
• The abnormality is of a degree that requires active management; e.g. change of dose , 1078  
discontinuation of the drug, more frequent follow -up assessments, further diagnostic investigation, 1079  
etc. 1080  
[IP_ADDRESS]  Hospi[INVESTIGATOR_059], Prolonged Hospi[INVESTIGATOR_146706]  1081  
Any adverse event that results in hospi[INVESTIGATOR_640189] 1082  
reported as a serious adverse event unless specifically instructed otherwise in this protocol.  Any 1083  
condition responsible for surgery should be documented as an adverse event if the condition meets the 1084  
criteria for any adverse event.   1085  
 1086  
Neither the condition, hospi[INVESTIGATOR_059], prolonged hospi[INVESTIGATOR_059], nor surgery are reported as an adverse 1087  
event in the following circumstances:  1088  
• Hospi[INVESTIGATOR_14841] a 1089  
preexisting co ndition.  Surgery should not be reported as an outcome of an adverse event if the 1090  
purpose of the surgery was elective or diagnostic and the outcome was uneventful.  1091  
• Hospi[INVESTIGATOR_14842].  1092  
• Hospi[INVESTIGATOR_14843], unless it 1093  
is a worsening or increase in frequency of hospi[INVESTIGATOR_640190] 1094  
investigator.  1095  
[IP_ADDRESS]  Pregnancy  [ADDRESS_856736] will not be evaluated as part of the PP population for timepoints after the pregnancy is 1101  
confirmed.  1102  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   30 
  1103  
Pregnancy by [CONTACT_640207] (SAE).  Hospi[INVESTIGATOR_272] a [ADDRESS_856737] be reported are those 1111  
that are:  1112  
• related to study participation,  1113  
• unexpected,  1114  
• serious or involve risks to  subjects or others , and  1115  
• serious adverse events  1116  
 1117  
For Narrative Reports of Safety Events  1118  
If the report is supplied as a narrative, the minimum necessary information to be provided at the time of 1119  
the initial report includes:  1120  
• Study identifier  
• Study Center  
• Subject number  
• A description of the event  
• Date of onset  • Current status  
• Whether study treatment was discontinued  
• The reason why the event is classified as serious  
• Investigator assessment of the association between 
the event and study treatment  
[IP_ADDRESS]  Investigator  reporting: notifying the IRB  1121  
Report Promptly, but no later than 5 working days:  1122  
Researchers are required to submit reports of the following problems promptly but  no later than 5 1123  
working days from the time the investigator becomes aware of the event:  1124  
Unant icipated problems including adverse events that are unexpected and related  1125  
• Unexpected : An event is “unexpected” when its specificity and severity are not accurately [ADDRESS_856738] labeling and package inserts.  1129  
• Related to the research procedures : An event is related to the research pro cedures if in the opi[INVESTIGATOR_1649] 1130  
of the principal investigator, the event was more likely than not to be caused by [CONTACT_53775] 1131  
procedures.  1132  
• Harmful: either caused harm to subjects or others, or placed them at increased risk  1133  
 1134  
Other Reportable events:  1135  
The following events also require prompt reporting to the IRB, though no later than 5 working days : 1136  
• Complaint of a research subject  when the complaint indicates unexpected risks or the 1137  
complaint cannot be resolved by [CONTACT_5051].  1138  
• Protocol deviations or violations  (includes intentional and accidental/unintentional deviations 1139  
from the IRB approved protocol) for any of the following situations:  1140  
o one or more participants were placed at increased risk of harm  1141  
o the event has the potential to occur again  1142  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856739] from immediate harm  1143  
• Breach of confidentiality  1144  
• Incarceration of a participant  when the research was not previously approved under Subpart C [ADDRESS_856740]  to remain on the study.  1146  
• New Information indicating a change to the risks or potential benefits  of the research, in 1147  
terms of severity or frequency. (e.g. analysis indicates lower -than-expected response rate or a [ADDRESS_856741]; Other r esearch finds arm of study has no therapeutic value; 1149  
FDA labeling change or withdrawal from market)  1150  
 1151  
Reporting Process  1152  
The reportable events noted above will be reported to the IRB using the form: “Reportable Event Form” 1153  
or as a written report of the event  (including a description of the event with information regarding its 1154  
fulfillment of the above criteria, follow -up/resolution and need for revision to consent form and/or other 1155  
study documentation).  1156  
 1157  
Copi[INVESTIGATOR_640191] 1158  
Investigator’s study file.  1159  
[IP_ADDRESS]  AE Reporting to Novo Nordisk  [ADDRESS_856742] the following information at minimum for each of these events : 1165  
• Study name  1166  
• Patient identification (e.g.  initials, sex, age)  1167  
• Event (preferably a diagnosis)  1168  
• Drug  1169  
• Reporter identification (e.g. Name, or initials)  1170  
• Causality  1171  
• Outcome  [ADDRESS_856743]’s participation i n a clinical trial, the investigator and institution will [ADDRESS_856744] for any study -related adverse events, including 1175  
clinically significant laboratory values related to the study. State that this medical care for study subjects 1176  
will be prov ided regardless of their insurance status.  1177  
 1178  
All adverse events classified as serious or severe or possibly/probably related to the trial product must be [ADDRESS_856745] been resolved. For cases of chronic 1180  
cond itions follow -up until the outcome category is “recovered” is not required, as these cases can be 1181  
closed with an outcome of “recovering” or “not recovered”.  [ADDRESS_856746] be followed until the outcome of the event is “recovering” (for chro nic 1184  
conditions), or “recovered” or until the end of the post -treatment follow -up stated in the protocol, [ADDRESS_856747] been resolved.  1186  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856748] party arising from or related to: (a) any breach of sponsor -investigator's obligations 1192  
or representations; or (b) sponsor -invest igator’s negligent or grossly negligent use or willful misuse of the [ADDRESS_856749] of competent jurisdiction or a duly appointed arb iter determines that such 1195  
losses or liability arose as a result of Novo Nordisk’s gross negligence, intentional misconduct, or [ADDRESS_856750]’s safety and would be instrumental in further treatment [ADDRESS_856751]’s treatment is unblinded, details of the time and reason for revealing must be documented i n [ADDRESS_856752]’s medical records and in the CRF and should be reported to DSMB in 48 hours.  1204  
8.5 Stoppi[INVESTIGATOR_1869]  1205  
• The trial will be terminated if two or more patients die within the 30 days of study drug 1206  
administration .  1207  
• The trial will be terminated if during the follow -up pe riod five or more of the first 50  patients 1208  
developed gastrointestinal or endocrine disorder leading to inpatient admission.  1209  
• The trial will be terminated if the DSMB determine that the study should be terminated.   [ADDRESS_856753] (DSMB)  1217  
[IP_ADDRESS]  DSMB Responsibilities  1218  
• Review the research protocol, informed consent documents, and plans for data safety;  1219  
• Review the following blinded data;  1220  
o baseline data  1221  
o safety data (mortality and morbidity)  1222  
o efficacy data  1223  
o study withdrawal due to non -compliance and AEs  1224  
o major protocol violation  1225  
• Review external data to the study when relevant information that may have an impact  on [ADDRESS_856754] safety becomes available;  1227  
• Review and evaluate ad hoc safety issues concerning the study at the request  by [CONTACT_15328] ; 1228  
and  1229  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   33 
 • Make recommendations to the investigators concerning continuation, termination, or other 1230  
modifications of the study based  on the observed beneficial or adverse effects of the study.  1231  
 1232  
All DSMB members will disclose their conflicts of interests before the study initiation and any updates 1233  
during the study period.  1234  
[IP_ADDRESS]  DSMB membership  [ADDRESS_856755] served as a member and chair of this 1238  
study and be willing to make firm commitment to participate as chair for the duration of the study.  1239  
 1240  
Members  1241  
Medical monitor (Chair):  an independent endocrinologist or gastroenterologist whose expertise 1242  
is in the treatment of obesity, cli nical trials, and statistical knowledge  1243  
Jose O Aleman, M. D. 1244  
Department of Medicine , NYUSOM, 212 -501-0585 , [EMAIL_12184]  1245  
 1246  
Physicians: an independent e ndocrinologist or gastroenterologist  1247  
 Elizabeth Weinshel, M.D.  1248  
Department of M edicine, NYUSOM, 212 -686-7500, [EMAIL_12185]  1249  
 1250  
Holly Lofton, M.D.  1251  
Department of Surgery, Medical Weight Loss Physician , NYUSOM, 212 -263-0883, 1252  
[EMAIL_12186]  1253  
 1254  
Christine Ren-Fielding, M.D.  1255  
Department of Surgery, Bariatric Surgeon, 212 -263-2174, christine.ren -[EMAIL_12187]  1256  
 1257  
Sean Heffron, M.D. , M.S., M.Sc.  1258  
Department of Medicine, Leon H. Charney Division of Cardiol ogy, [PHONE_13301] , 1259  
sean.heffron @nyumc.org  1260  
[IP_ADDRESS]  Projected Schedule of Meetings  1261  
Initial Meeting:  An initial meeting of the DSMB will be held prior to any subject enrollment in order to 1262  
review the protocol, establish a distribution and meeting schedules, the study modification, termination 1263  
guidelines, and reports formats.  This meeting will be done vi a e-mail or telephone conference.  1264  
 1265  
Regular DSMB Meetings:  Subsequent DSMB meetings will be held to review and discuss study data 1266  
according to the schedule as described in the table below.  This meeting will be done via telephone 1267  
conference or in -person meeting after distributing the data/reports via e -mail.  [ADDRESS_856756] 25  patients were 
enrolled.  Entire DSMB  baseline data  
safety data (mortality and morbidity)  
efficacy data  
study withdrawal due to non -compliance and 
AEs 
accrual and withdrawal rates  
major protocol violation  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856757] 50  patients were 
completed.  Entire DSMB  baseline data  
safety data (mortality and morbidity)  
efficacy data  
study withdrawal due to non -compliance and 
AEs 
accrual and withdrawal rates  
major p rotocol violation  
external data to the study if available  
When the f irst 100  patients were 
completed.  Entire DSMB  safety data (mortality and morbidity)  
efficacy data  
study withdrawal due to non -compliance and 
AEs 
accrual and withdrawal rates  
major protocol violation  
study conduct issues  
external data to the study if available  
Upon completion ( 132 patients) or 
termination of study  Entire DSMB  safety data (mortality and morbidity)  
efficacy data  
study withdrawal due to non -compliance and 
AEs 
accrual and withdrawal rates  
major protocol violation  
study conduct issues  
external data to the study if available  
 1270  
Ad Hoc meetings: An ad hoc meeting will be called at any time by [CONTACT_640208] [ADDRESS_856758] safety issues arise.  If a significant safety concern arises during the study, the 1272  
DSMB chair or PI [INVESTIGATOR_640192] a meeting to review safety and any ot her aspects of the study.  1273  
 1274  
Significant safety events may include, but are not limited to the followings:  1275  
• A death or life -threatening condition sustained by a study subject, regardless of causality  1276  
• An unexpected serious safety issue newly identified that c ould expose participants to 1277  
unnecessary risks.  1278  
 1279  
The above case may require suspension or termination of study if DSMB review confirms that the risks 1280  
are too high to continue the study enrollment  1281  
 1282  
Proposed study amendments that significantly alter the treat ment plan and /or deal with subject safety 1283  
concerns will prompt an ad hoc meeting for review prior to implementation of changes.  This may require 1284  
suspension of enrollment pending DSMB review.  1285  
[IP_ADDRESS]  Meeting Format  [ADDRESS_856759]’s treatment group . AE repor ts will include the followings.  1293  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   35 
 • Name [CONTACT_534173]  1294  
• Onset and end date  1295  
• UAE  1296  
• Severity (mild, moderate, severe)  1297  
• Seriousness  1298  
• Relationship to the study drug/ procedure  1299  
• Action taken  1300  
• Outcomes  1301  
 1302  
All reports will be submitted by [CONTACT_9137].  1303  
 1304  
Meeting Minutes: Minutes of DSMB meetings will be distributed to members, all investigators, and 1305  
study personnel within 4 weeks and also to IRB annually if available.   1306  
Minutes include at a minimum:  1307  
• Protocol number and study title  1308  
• DSMB meeting date  1309  
• Copy of agenda  1310  
• A list of attendances, including DSMB members and any other people present, listing their 1311  
professional title and role at the meeting  1312  
• Information reviewed and related discussion during the meeting  1313  
• DSMB recommendations including clear and concise rati onale  1314  
 1315  
Communications  1316  
The DSMB chair communicates directly with the investigators to allow them the opportunity to ask 1317  
questions and discuss any recommendations.  If the investigator(s) accepts the recommendations of the 1318  
DSMB, the investigator(s) will be r esponsible for implementing the actions in response.  In the event the [ADDRESS_856760] be amended, the investigator will prepare and submit the amendment to the DSMB for 1320  
approval prior to implementing amendment changes.  1321  
[IP_ADDRESS]  Reportable Adverse Events  1322  
All SAEs will be reported to all DSMB member and all investigators via e -mail within one  or two  1323  
working day of learning of the event.   A summary of all adverse events, (previously reported or not, 1324  
serious or not) will be submitted to the DSMB as described in this plan.  1325  
 1326  
All unexpected serious adverse events will be reported to IRB , DSM B, and Novo Nordisk  regardless the 1327  
relationship to the study drug.  1328  
[IP_ADDRESS]  DSMB Considerations and Policies  1329  
Stoppi[INVESTIGATOR_1869]: After reviewing/considering the information, the DSMB will determin e whether the 1330  
study should continue as planned, proceed with modifications, or be terminated.  The justification to 1331  
terminate the study may be due to the DSMB’s analysis that there is overwhelming safety issue.   [ADDRESS_856761] the loss of confidentiality, all study information will be stored using REDCap  1335  
(Research Electronic Date Capture)  database, which is a commonly used, secure, web -based system that [ADDRESS_856762]’s identifiers.  No 1338  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856763] of 1996 (HIPAA).  Those regulati ons require a [ADDRESS_856764] of the following:  1348  
• What protected health information (PHI) will be collected from subjects in this study  1349  
• Who will have access to that information and why  1350  
• Who will use or disclose that informa tion  1351  
• The rights of a research subject to revoke their authorization for use of their PHI.  [ADDRESS_856765] vital status (i.e. that the subject is alive) at the end of their scheduled s tudy 1356  
period.  1357  
9.3 Source Documents  1358  
Source data is all information, original records of clinical findings, observations, or other activities in a 1359  
clinical trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in 1360  
source do cuments.  Examples of these original documents, and data records include: hospi[INVESTIGATOR_1097], 1361  
clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, [ADDRESS_856766] files, and records kept at the pharmacy, at the laboratories, and at medico - 1365  
technical departments involved in the clinical trial.  1366  
9.4 Case Report Forms  1367  
The study case report form (CRF) is the primary data collection instrument for the study.  All data [ADDRESS_856767] be explained.  If a space on the CRF is 1369  
left blank because the procedure was not done or the question was not asked, write “N/D”.  If the item is 1370  
not applicable to the individual case, write “N/A”.  All entries should be printed legibly in black ink.  If [ADDRESS_856768] be initialed and dated.  DO NOT ERASE 1373  
OR WHITE OUT ERRORS.  For clarification of illegible or uncertain entrie s, print the clarification 1374  
above the item, then initial and date it.  1375  
 1376  
All research data will be collected in Case Report Forms (CRFs). Clinical safety data, labs, screening [ADDRESS_856769] access to patient data and these include: the PI [INVESTIGATOR_7966], sub-investigators, the research 1384  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   37 
 coordinator  and the  research assistant .  Though the information collected in this study may be pu blished, 1385  
no patient will be identified by [CONTACT_640209].  1386  
9.5 Records Retention  1387  
It is the investigator’s responsibility to retain study essential documents for at least 2 years after 1388  
completion of the study. These documents will be retained  for a longer period if required by [CONTACT_202165] 1389  
with Novo Nordisk .  In such an instance, it is the responsibility of Novo Nordisk  to inform the 1390  
investigator/institution as to when these documents no longer need to be retained.  [ADDRESS_856770] (IRB) according to the IRB’s 1397  
reporting requirements.  The investigator will allocate adequate time for such monitoring activities.  The 1398  
Investigator will also ensure that the monitor or other compliance or quality assurance reviewer is given 1399  
access to all the above noted study -related documents and study related facilities (e.g. pharmacy, 1400  
diagnostic laboratory, etc.), and has adequate space to conduct the monitoring visit.  1401  
10.2 Auditing and Inspecting  1402  
The investigator will permit study -related monitoring, audits, and inspections by [CONTACT_1201]/EC , Novo 1403  
Nordisk , government regulatory bodies, and Univ ersity compliance and quality assurance groups of all 1404  
study related documents (e.g. source documents, regulatory documents, data collection instruments, study 1405  
data etc.).  The investigator will ensure the capability for inspections of applicable study -related facilities 1406  
(e.g. pharmacy, diagnostic laboratory, etc.).  [ADDRESS_856771] 1416  
(IRB) or indep endent Ethics Committee (EC) in agreement with local legal prescriptions, for formal [ADDRESS_856772].  The deci sion of the IRB/EC  concerning the conduct of the study will be [ADDRESS_856773], using the IRB/EC -approved consent form, must be obtained before that subject undergoes any [ADDRESS_856774] or le gally acceptable surrogate, and the 1427  
investigator -designated research professional obtaining the consent.  1428  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856775] with this study (patent ownership, royalties, or financial 1433  
gain greater than the minimum allowable by [CONTACT_1385], etc.) must have the conflict reviewed by a [ADDRESS_856776] for the research related  components (study drugs, visits, tests, procedures ). [ADDRESS_856777] of the study, patients will be paid in gift cards up to $[ADDRESS_856778] if the visit is completed within the time 1443  
below.  1444  
• $50 - Visit 2 (3 month +/ - [ADDRESS_856779] day of study drug)  1445  
• $50 - Visit 3 (6 months + /- [ADDRESS_856780] day of study drug)  1446  
• $50 - Visit 4 (9 months +/ -  [ADDRESS_856781] day of study drug ) 1447  
• $100 - Visit 5 (12 months +/ - [ADDRESS_856782] day of study drug ) [ADDRESS_856783] results and all data derived from the study.  1457  
 1458  
PI [INVESTIGATOR_640193] a manuscript of submission(s) for revi ew and comment.  PI [CONTACT_221198] 1459  
publish any manuscript without Novo Nordisk ’s prior approval.  1460  
1461  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   39 
  1462  
14 References  1463  
 1464  
1. Courcoulas, A.P., et al., Weight change and health outcomes at 3 years after bariatric surgery 1465  
among individuals with severe obesity.  JAMA, 2013. 310(22): p. 24 16-25. 1466  
2. Christou, N.V., D. Look, and L.D. Maclean, Weight gain after short - and long -limb gastric 1467  
by[CONTACT_640210] 10 years.  Ann Surg, 2006. 244(5): p. 734 -40. 1468  
3. Sjostrom, L., et al., Lifestyle, diabetes, and cardiovascular ri sk factors 10 years after bariatric 1469  
surgery.  N Engl J Med, 2004. 351(26): p. 2683 -93. 1470  
4. Himpens, J., et al., Outcomes of revisional procedures for insufficient weight loss or weight 1471  
regain after Roux -en-Y gastric by[CONTACT_6476].  Obes Surg, 2012. 22(11): p. 1746 -54. 1472  
5. Hallowell, P.T., et al., Should bariatric revisional surgery be avoided secondary to increased 1473  
morbidity and mortality?  Am J Surg, 2009. 197(3): p. 391 -6. 1474  
6. Vilsboll, T., et al., Effects of glucagon -like peptide -1 receptor agonists on weight loss: systematic 1475  
review and meta -analyses of randomised controlled trials.  BMJ, 2012. 344: p. d7771.  1476  
7. Wadden, T.A., et al., Weight maintenance and additional weight loss with liraglutide after low - 1477  
calorie -diet-induced weight loss: the SCALE Maintenance r andomized study.  Int J Obes (Lond), 1478  
2013. 37(11): p. 1443 -51. 1479  
8. Pi-Sunyer, X., et al., A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight 1480  
Management.  N Engl J Med, 2015. 373(1): p. 11 -22. 1481  
9. Habegger, K.M., et al., GLP -1R agonism enhances a djustable gastric banding in diet -induced 1482  
obese rats.  Diabetes, 2013. 62(9): p. 3261 -7. 1483  
10. Larsen, P.J., et al., Systemic administration of the long -acting GLP -1 derivative NN2211 induces 1484  
lasting and reversible weight loss in both normal and obese rats.  Diabetes, 2001. 50(11): p. 2530 - 1485  
9. 1486  
11. Raun, K., P. von Voss, and L.B. Knudsen, Liraglutide, a once -daily human glucagon -like 1487  
peptide -1 analog, minimizes food intake in severely obese minipi[INVESTIGATOR_14107].  Obesity (Silver Spring), 1488  
2007. 15(7): p. 1710 -6. 1489  
12. Raun, K., et al., Liraglutide, a long -acting glucagon -like peptide -1 analog, reduces body weight 1490  
and food intake in obese candy -fed rats, whereas a dipeptidyl peptidase -IV inhibitor, vildagliptin, 1491  
does not.  Diabetes, 2007. 56(1): p. 8 -15. 1492  
13. Astrup, A., et al., Effects of liraglutide in the treatment of obesity: a randomised, double -blind, 1493  
placebo -controlled study.  Lancet, 2009. 374(9701): p. 1606 -16. 1494  
14. Astrup, A., et al., Safety, tolerability and sustained weight loss over 2 years with the once -daily 1495  
human GLP -1 analog, liraglutide.  Int J Obes (Lond), 2012. 36(6): p. 843 -54. 1496  
15. van Can, J., et al., Effects of the once -daily GLP -1 analog liraglutide on gastric emptying, 1497  
glycemic parameters, appetite and energy metabolism in obese, non -diabetic adults.  Int J Obes 1498  
(Lond), 2014. 38(6): p. 784 -93. 1499  
16. Peterson, G.E. and R.D. Pollom, Liraglutide in clinical practice: dosing, safety and efficacy.  Int J [ADDRESS_856784], 2010(167): p. 35 -43. 1501  
 1502  
1503  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   40 
  1504  
15 Attachments  1505  
15.1 Attachment 1 - Study Procedures  1506  
15.2 Attachment 2 - PHQ ( Patient Health Questionnaire ) 1507  
15.3 Attachment 3 - International P hysical Activity Q uestionnaire (IPAQ)  [ADDRESS_856785]  1510  
 1511  
 1512  
 1513  
1514  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   41 
  1515  
ATTACHMENT 1  1516  
Visit Number  1   2   3   4   5 
 Baseline  1M 2M 3 
months  4M 5M 6 
months  7M 8M 9 
months  10M  11M  12 
months  
Visit window  0-4 wks 
prior to 
the 
treatment    
± 4 wks    
± 4 wks    
± 4 wks    
± [ADDRESS_856786] & 
Neck 
Circumference  X   
X   
X   
X   
X 
Height  X             
Medications  X   X   X   X   X 
Blood 
Pregnancy 
Test (Beta 
Quantitative 
HCG)  (Only 
applicable 
for women of 
childbearing 
potential)  X   
X   
X   
X   
X 
1BMP, 
HbA1c, 1Lipid 
profile, 
Amylase, 
Lipase  X   
X   
X   
X   
X 
Additional 
plasma and 
serum for 
future 
analyses  X   
   
X   
   
X 
PHQ -9, IPAQ, 
[ADDRESS_856787]  X   
X   
X   
X   
X 
Body 
Composition  X   X   X   X   X 
Comorbidities:  
Diabetes, 
Hypertension, 
STOP -BANG  X   
X   
X   
X   
X 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   42 
 2AEs X X X X X X X X X X X X X 
Study 
Medication 
Compliance 
Phone call   X X  X X  X X  X X  
1. Fasting is required  1517  
2. Ask about hypoglycemia symptoms  for patients with Type 2 DM  1518  
 1519  
 1520  
 1521  
 1522  
 1523  
 1524  
 1525  
 1526  
 1527  
 1528  
1529  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   43 
  1530  
ATTACHMENT 2:  1531  
[IP_ADDRESS]  PHQ -9 (Patient Health Questionnaire Nine Symptom Checklist)  [ADDRESS_856788] you been bothered by [CONTACT_640211]?  Not at all  Several days  More than half 
the days  Nearly every day  
1. Little interest or pleasure in 
doing things  0 1 2 3 
2. Feeling down, depressed, or 
hopeless  0 1 2 3 
3. Trouble falling or staying 
asleep, or sleepi[INVESTIGATOR_33606]  0 1 2 3 
4. Feeling tired or having little 
energy  0 1 2 3 
5. Poor appetite or overeating  0 1 2 3 
6. Feeling bad about yourself —or 
that you are a failure or have let 
yourself or your family down  [ADDRESS_856789] 
noticed? Or the opposite —being 
so fidgety or restless that you have 
been moving around a lot more 
than usual  [ADDRESS_856790]  0 1 2 3 
(For office coding: Total Score ____ = ____ + ____ + ____)  
If you checked off any problems, how difficult  have these problems made it for you to do your 1534  
work, take care of things at home, or get along with other people?  1535  
Not difficult at all  Somewhat difficult  Very difficult  Extremely difficult  
□ □ □ □ 
 1536  
 1537  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   44 
 ATTACHMENT 3  1538  
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE  1539  
(AUGUST 2002)  [ADDRESS_856791] 7 DAYS SELF -ADMINISTERED FORMAT  1541  
FOR USE WITH YOUNG AND MIDDLE -AGED ADULTS (15 -69 years)  1542  
 1543  
THE INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRES (IPAQ) COMPRISES A 1544  
SET OF 4 QUESTIONNAIRES. LONG (5 ACTIVITY DOMAINS ASKED INDEPENDENTLY) 1545  
AND SHORT (4 GENERIC ITEMS) VERSIONS FOR USE BY [CONTACT_640212] 1546  
SELF -ADMINISTERED METHODS ARE AVAILABLE. THE PURPOSE OF THE 1547  
QUESTIONNAIRES IS TO PROVIDE COMMON INSTRUMENTS THAT CAN BE USED TO 1548  
OBTAIN INTERNATIONALLY COMPARABLE DATA ON HEALTH –RELATED PHYSICAL 1549  
ACTIVITY.  1550  
 1551  
BACKGROUND ON IPAQ  1552  
THE DEVELOPMENT OF AN INTERNATIONAL MEASURE FOR PHYSICAL ACTIVITY 1553  
COMMENCED IN GENEVA IN 1998 AND WAS FOLLOWED BY [CONTACT_640213] 1554  
AND VALIDITY TESTING UNDERTAKEN ACROSS 12 COUNTRIES (14 SITES) DURING [ADDRESS_856792] the psychometric 1562  
properties of the instruments.  1563  
Translation  from English and Cultural Adaptation  1564  
Translation from English is supported to facilitate worldwide use of IPAQ. Information on the availability 1565  
of IPAQ in different languages can be obtained at  www.ipaq.ki.se . If a n ew translation is undertaken we 1566  
highly recommend using the prescribed back translation methods available on the IPAQ website. If 1567  
possible please consider making your translated version of IPAQ available to others by [CONTACT_640214] 1568  
the IPAQ website. Fur ther details on translation and cultural adaptation can be downloaded from the 1569  
website.  1570  
16 Further Developments of IPAQ  1571  
International collaboration on IPAQ is on -going and an International Physical Activity Prevalence Study  1572  
is in progress. For further information see the IPAQ website.  1573  
More Information  1574  
More detailed information on the IPAQ process and the research methods used in the development of 1575  
IPAQ instruments is available at www.ip aq.ki.se  and Booth, M.L. (2000).  Assessment of Physical 1576  
Activity: An International Perspective .  Research Quarterly for Exercise and Sport, 71 (2): s114 -20.  [ADDRESS_856793] 7 1581  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856794] bicycling?  1591  
_____  days per week   1592  
 1593  
   No vigorous physical activities   Skip to question 3  1594  
 1595  
2. How much time did you usually spend doing vigorous  physical activities on one of those days?  1596  
_____  hours per day   1597  
_____  minutes per day   1598  
 Don’t know/Not sure  [ADDRESS_856795] 7 days , on h ow many days did you do moderate  physical activities like carrying 1604  
light loads, bicycling at a regular pace, or doubles tennis?  Do not include walking.  1605  
_____  days per week  1606  
 1607  
   No moderate physical activities   Skip to question 5  1608  
 1609  
4. How much time did you us ually spend doing moderate  physical activities on one of those days?  1610  
_____  hours per day  1611  
_____  minutes per day  1612  
 Don’t know/Not sure  [ADDRESS_856796] 10 minutes at a time?   1619  
_____  days per week  1620  
  1621  
   No walking      Skip to question 7  1622  
 1623  
6. How much time did you usually spend walking  on one of those days?  1624  
_____  hours per day  1625  
_____  minutes per day   1626  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   46 
  Don’t know/Not sure  [ADDRESS_856797] 7 days , how much time did you spend sitting  on a week day ? 1631  
_____  hours per day   1632  
_____  minutes per day   1633  
  Don’t know/Not sure  1634  
This is the end of the questionnaire, thank you for participating.  1635  
1636  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   47 
 Attachment 4  1637  
24 Hour Food/Drink Recall    
Breakfast    
Food/Drinks Item  Amount 
consumed  Serving unit (i.e.  slice, cup, 
tablespoon, ounce)  
      
      
      
      
Lunch    
Food/Drinks Item  Amount 
consumed  Serving unit (i.e. slice, cup, 
tablespoon, ounce)  
      
      
      
      
      
Dinner    
Food/Drinks Item  Amount 
consumed  Serving unit (i.e.  slice, cup, 
tablespoon, ounce)  
      
      
      
      
      
Snacks    
Food/Drinks Item  Amount 
consumed  Serving unit (i.e. slice, cup, 
tablespoon, ounce)  
      
      
      
      
      
Desserts    
Food/Drinks Item  Amount 
consumed  Serving unit (i.e. slice, cup, 
tablespoon, ounce)  
      
      
      
      
 1638  
ATTACHMENT 5  1639  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/[ADDRESS_856798]  1640  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   49 
 Name:  [CONTACT_1782]:  
Goal of  this diet is to eat protein  with  every  meal  and snack  and decrease  carbohydrate  intake  as the day progresses - No fried  food  
 Portion  mate 
cylinder  color  Red Orange  Green  Yellow  Purple  Water  
 
 
Meal  Type   
 
Recommendations  All meats,  poultry, 
fish, seafood,  tofu, 
eggs, egg  whites  All carbohydrate 
Non -preferred  fruits   
All vegetables  Preferred fruits  List 
(Apple, pear,  raspberry, 
blackberry,  blueberry)  Fat, cheese,  
oils,  nuts, 
seeds  Drink  48- 
64 oz.  (1.5 
to 2 liters)  
 Refer to starch  list 
(avoid after 6  pm) Not including veggies  in 
the starch  list Up to 1 serving each  day 
(avoid after 6  pm)  Up to 2  serving 
each  day Avoid  soda  
and juice  
  Write down number  of 
portions you ate (i.e.  1, 
2,3) Write down number  of 
portions you ate (i.e.  1, 
2,3) Write down number  of 
portions you ate (i.e.  1, 
2,3)  
Write down number  of 
portions you ate (i.e. 1,  2,3) Write  down 
number of  portion 
you ate (i.e.  1, 
2,3) Write  down 
number of  oz. 
you drank  
Breakfast 
Eat calories 
within  1-[ADDRESS_856799],  then 
protein  Up to 1  Red 
Up to 1  Green  
(No Orange)        
Snack  1        
Snack  2        
Other  food         
Exercise  Number of  Steps:     Other  exercise:  minutes  
IDEAL  SNACKS  - 6 OZ NONFAT  OR LOW  FAT  GREEK  YOGURT  (MUST  HAVE  MORE  PROTEIN  GRAMS  THAN  CARB  GRAMS)  , 1-[ADDRESS_856800]  BEEF  (NO MARBLED  MEATS:  
PEPPERONI,  SALAMI,  ETC.),  1/[ADDRESS_856801]  ABOVE  
Activity  
• Goal of 150 minutes of exercise weekly - You can split this up however you would  like 
• You may want to use a Pedometer – Ultimate goal of at least 10,[ADDRESS_856802] 20 times before  swallowing  
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   1 
 PREFERRED  STARCHES  NON -PREFERRED  STARCHES  
BREAD  BREAD  
Bread,  pumpernickel  Bagel  
Bread,  rye Biscuit  
Bread, whole  wheat  Bread,  white  
Bread, reduced  calorie  English  Muffin  
English muffin, whole  wheat  Hot dog bun or Hamburger  bun 
Pancake, whole  wheat  Naan  
Pi[INVESTIGATOR_17399], whole  wheat  Pancake  
Tortilla,  wheat  Pi[INVESTIGATOR_640194], corn or  flour  
 Waffle  
  
CEREAL AND  GRAINS  CEREAL AND  GRAINS  
Bran  cereals  Cornmeal  
Bulgar  Granola  
Cereals,  cooked  Grits  
Cereals,  unsweetened  Pasta,  white  
Couscous  Puffed  cereal  
Kasha  Rice,  white  
Millet  Sugar -frosted  cereal  
Muesli   
Oats   
Pasta, whole  wheat   
Rice,  brown   
Shredded  wheat   
Wheat  germ   
  
STARCHY  VEGETABLES  STARCHY  VEGETABLES  
Corn  Baked  beans  
Corn on the  cob French -fried  potatoes  
Mixed vegetables with corn and  peas  Potato,  boiled  
Peas,  green  Potato,  mashed  
Plantain   
Potato, baked with  skin  
Squash, winter (acorn, butternut,  pumpkin)   
Yam, sweet potato, plain with  skin  
  
CRACKERS AND  SNACKS  CRACKERS AND  SNACKS  
Popcorn (no fat or low -fat microwave)  Animal  crackers  
Rice cakes  Chow mein  noodles  
Snack chips, fat free or baked (tortilla,  potato)  Crackers, round butter  type 
Universal Trial Number: U1111 -1178 -7319                Version 7: 10/11/2019                            Page   2 
 PREFERRED STARCHES  NON -PREFERRED STARCHES  
Whole wheat crackers, no fat  added  Graham  cracker  
 Matzoh  
 Oyster  crackers  
 Pretzels  
 Saltine -type  crackers  
 Sandwich crackers, cheese or peanut  filling  
  
BEANS, PEAS AND LENTILS  BEANS, PEAS AND LENTILS  
Beans/peas (garbanzo, pi[INVESTIGATOR_1946], kidney,  white)   
Hummus   
Lima  beans   
Lentils   
Miso   
  
FRUIT  FRUIT  
Apple, unpeeled,  small  Apples,  dried  
Applesauce,  unsweetened  Apricots,  fresh  
Blackberries  Apricots,  dried  
Blueberries  Banana  
Pear,  fresh  Cantaloupe  
Raspberries  Cherries,  fresh  
 Cherries, sweet,  canned  
 Dates  
 Figs,  dried  
 Fruit  cocktail  
 Grapefruit  
 Grapes  
 Honeydew  melon  
 Kiwi  
 Mandarin oranges,  canned  
 Mango  
 Nectarine  
 Orange  
 Papaya  
 Peach,  fresh  
 Peaches,  canned  
 Pears,  canned  
 Pi[INVESTIGATOR_70945],  fresh  
 Pi[INVESTIGATOR_70945],  canned  
 Plums  
 Raisins  
 Tangerines  
 Strawberries  
 Watermelon  
 